Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.75 |
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 8/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28130084 | 0.85 | RAB9A (1.00) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL8043048 | 0.83 | RAB9A (0.77) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL20513984 | 0.80 | ALDH1A1 (0.66) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL20620309 | 0.77 | RAB9A (0.73) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL11922435 | 0.76 | CA1 (0.73) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL9528874 | 0.76 | MAPT (1.00) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL31090324 | 0.76 | GAA (0.62) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL10016495 | 0.76 | RAB9A (0.71) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL7693650 | 0.76 | GAA (1.00) | ALDH1A1RAB9ALMNAMAPTNPC1 | |
| SCHEMBL28640790 | 0.75 | GAA (0.61) | ALDH1A1RAB9ALMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| WO-2015184011-A2 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-03 | — | — | WO | disclosed |
| US-6080772-A | 2-AMINOTHIAZOLE TRIAZOLE OR TETRAZOLE COMPOUND FOR REGULATING PROTEIN TYROSINE PHOSPHATASE ACTIVITY | SUGEN, INC. (US) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885RAB9A 2081/4885LMNA 2152/4885 |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885RAB9A 2081/4885LMNA 2152/4885 |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885RAB9A 2081/4885LMNA 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.